Filing Flows › Comparisons › RLAY vs PLUR
Relay Therapeutics vs Pluri: RLAY and PLUR compared
Relay Therapeutics is the larger company: $350K of revenue in its latest quarter (Q2 2026) against $335K for Pluri (Q4 FY26). Pluri is growing faster (-16% against -48% a year earlier).
Where the money goes: RLAY and PLUR
Relay Therapeutics (RLAY) · Q2 2026
Relay Therapeutics, Q2 2026: revenue $350K (-48% year over year), net loss $83.7M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Pluri (PLUR) · Q4 FY26
Pluri, Q4 FY26: revenue $335K (-16% year over year), net loss $6.2M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
| Relay Therapeutics (RLAY) | Pluri (PLUR) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 FY26 |
| Revenue | $350K | $335K |
| Revenue growth, Y/Y | -48% | -16% |
| Operating margin | n/m | n/m |
| Net earnings | −$83.7M | −$6.2M |
| Operating cash flow | −$54.1M | −$4.4M |
Questions
Which is bigger, Relay Therapeutics or Pluri?
Relay Therapeutics is the larger company: $350K of revenue in its latest quarter (Q2 2026) against $335K for Pluri (Q4 FY26).
Is Relay Therapeutics or Pluri growing faster?
Pluri is growing faster (-16% against -48% a year earlier).
More: Relay Therapeutics earnings · how Relay Therapeutics makes money · Pluri earnings · how Pluri makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-K filed Sep 10, 2026). Fiscal quarters can end on different dates. Not investment advice.